Publications

Our scientific publications in high-quality journals reflect the quality of the innovative research in Entasis’ laboratories.

Search by Program

Durand-Réville TF, Comita-Prevoir J, Zhang J, Wu X, May-Dracka T, Romero T, Wu F, Chen A, Shapiro AB, Carter N, McLeod S, Giacobbe R, Verheijen J, Lahiri S, Sacco M, Chen Y, O’Donnell J, Miller AA, Mueller JP, and Tommasi R

Discovery of an orally available diazabicyclooctane inhibitor (ETX0282) of class A, C and D serine β-lactamases

Journal of Medicinal Chemistry (2020)

Lickliter JD, Lawrence K, O’Donnell J, and Isaacs R

Safety, pharmacokinetics, and drug-drug interaction potential of intravenous durlobactam, a β-lactamase inhibitor, in healthy subjects

Antimicrobial Agents and Chemotherapy (2020)

Seifert H, Muller C, Stefanik D, Higgins PG, Miller A and Kresken M

In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii

Journal of Antimicrobial Chemotherapy (2020)

Yang Q, Xu Y, Jia P, Zhu Y, Zhang J, Zhang G, Deng J, Hackel M, Bradford PA, and Reinhart H

In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China

Journal of Antimicrobial Chemotherapy (2020)

Sagan O, Yakubsevitch R, Yanev K, Fomkin R, Stone E, Hines D, O’Donnell J, Miller A, Isaacs R, and Srinivasan S

Pharmacokinetics and tolerability of intravenous sulbactam-durlobactam with imipenem-cilastatin in hospitalized adults with complicated urinary tract infections, including acute pyelonephritis

Antimicrobial Agents and Chemotherapy (2020)

McLeod SM, Moussa SH, Hackel MA, and Miller AA

In vitro activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex isolates collected globally from 2016-2017

Antimicrobial Agents and Chemotherapy (2020)

O’Donnell J, Preston RA, Mamikonyan G, Stone E, and Isaacs R

Pharmacokinetics, safety, and tolerability of intravenous durlobactam and sulbactam in subjects with renal impairment and healthy matched control subjects

Antimicrobial Agents and Chemotherapy (2019)